Drug product formulations hold a crucial role in determining the magnitude of drug bioavailability. Bioavailability refers to the percentage of an administered dose that enters the systemic circulation in an active form. Optimizing formulations can significantly enhance this process, leading to more effective drug delivery and therapeutic outcomes.

Eli Lilly and Company has taken the lead in in the production of tirzepatide, a groundbreaking drug for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, exhibits significant ability to improve glycemic control and reduce the risk of cardiovascular disease. The complex manufacturing process of tirzepatide requires a series of met